Short answer
Kodiak Sciences Inc. (KOD) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$66M
- −20.9% YoY · −12.9% QoQ
- EPS (diluted)
- −$1.05
- −1.9% YoY · −11.7% QoQ
Source: XBRL data from the Kodiak Sciences Inc. (KOD) Q2 2026 10-Q on SEC EDGAR. USD.
Kodiak Sciences Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue: precommercial biotechnology company; no quarterly revenue disclosed
- Operating loss $66.8M vs $55.5M YoY; net loss $65.6M vs $54.3M
- R&D expense $56.1M vs $42.8M, driven by KSI-101 $12.3M and KSI-501 $12.7M
- Cash position, operating cash flow, and capital deployment: no figures provided in supplied text
- DAYBREAK topline data expected September 2026; BLA submission for Zenkuda intended in 2026
Risk Factors
- No material-change statement provided; filing emphasizes continued clinical-stage status with no approved products or revenue
- Clinical efficacy risk: tarcocimab failed primary endpoints in DAZZLE, GLEAM and GLIMMER trials
- Regulatory risk: FDA may reject AI-based DAYBREAK dosing or require separate review before labeling
- Operational risk: Enrollment continues in Phase 3 PEAK, PINNACLE and ALTO trials, creating delay exposure
- Safety risk: Unexpected cataract increases observed in tarcocimab arms of GLEAM and GLIMMER trials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kodiak Sciences Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.